Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI
Authors:
- 1 November 2014
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 87, 843-861
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Alzheimer Mechanisms and Therapeutic StrategiesCell, 2012
- Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevantNeuroImage, 2012
- Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B dataAnnals of Neurology, 2011
- Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimagingNeuroImage, 2011
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer diseaseNeurobiology of Aging, 2009
- Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic miceNeurobiology of Aging, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004